The Endocrine Society influences a wide range of policies affecting endocrine-related research and practice. The organization’s priorities include: increased funding for the
National Institutes of Health (NIH); ensuring access to adequate, affordable healthcare; improved regulation of
endocrine-disrupting chemicals (EDCs) in the United States and internationally, realigning physician payment to recognize the value endocrinologists bring to the health care system; reduction in the prevalence of
diabetes and
obesity, protecting access to care for women and
transgender patients; improved research policy; and increased awareness of the impact of
climate change on endocrine health.
Insulin affordability has become an increasingly prevalent issue for people living with diabetes. The Endocrine Society's advocacy team supports insulin affordability for all; the Endocrine Society advocates for the
Inflation Reduction Act to limit cost-sharing to a copay of no more than $35 and cap costs at no more than $100 per month. Additionally, the Endocrine Society has partnered with IPEN to raise awareness of health risks associated with endocrine-disrupting chemicals. Experts in the field have developed a guide for public interest organization and policy makers urging them to prioritize specific actions on EDCs, including a coherent identification process linked to control measures to reduce widespread exposures. In 2023, Delia M. Sosa and other members of the American Medical Association’s Medical Student Section authored a resolution with the Endocrine Society that led to the
American Medical Association strengthening its position on protecting
gender-affirming care. This resolution advocated against legislation criminalizing access to gender-affirming healthcare and supported efforts to oppose discriminatory policies. ==Science in the news==